Extended Data Fig. 3: Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials. | Nature Medicine

Extended Data Fig. 3: Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials.

From: Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Extended Data Fig. 3

Solid line: median. Shaded area: 95% prediction interval. Predictions made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, using observed serum concentration data18,19. The viruses circulating in each trial are: (a) the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; (b) the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT80 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT80 titers10.

Back to article page